Ancora Issues Letter to CSXs Board of Directors Regarding the Need to Avert a Permanent Impairment of Value and Aggressively Pursue a Value-Maximizing Merger
Asserts the Board Should Immediately Announce the Formal Retention of an Investment…
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global…
SimCorp names Peter Sanderson as Chief Executive Officer
Sanderson has proven track record of driving growth and deep industry knowledge Sanderson…
A New Chapter of Bold Leadership and Unstoppable Growth
LEHI, Utah, July 24, 2025 /PRNewswire/ -- Amare Global, The Mental Wellness…
Prime Success Issues Statement on New York State Court Decision Confirming Our Rights as Sinovac Shareholders Including Right to Vote at Upcoming Special Meeting
Corrects the Record Following Latest Attempt By the 1Globe Activist Board to…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Jack Burnett ("CEO") today announced…